response to idac + mitox was influenced by sensitivity to previous therapy : patients with primary refractory and early relapse aml responded less well to the regimen ( cr rate 28 % and 33 % , respectively ) , as compared to those with previously untreated ( cr rate 64 % ) or late relapse disease ( cr rate 85 % ) .
C0026259
mitox
C0023467
aml